Last reviewed · How we verify
NCT04483245: CAPTURE
Platelet Activation by a Collagen Analogue in Hemorrhagic Situations
trial testing Blood sampling in Collagen Analog in 83 participants. Completed in 11 April 2023.
11 April 2023
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire Dijon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 83 |
| Start date | 7 December 2021 |
| Primary completion | 11 April 2023 |
| Estimated completion | 11 April 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Blood sampling — full drug profile →
Conditions studied
- Collagen Analog — all drugs for Collagen Analog →
- Platelet Activation — all drugs for Platelet Activation →
- Hemorrhage — all drugs for Hemorrhage →
Sponsor
Centre Hospitalier Universitaire Dijon
Who can join
18 and older, any sex, with Collagen Analog or Platelet Activation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dijon University Hospital and the Dijon-based NVH Medicinal Company have developed a recombinant mini-collagen NVH020B with platelet and Willebrand factor binding activity. Its small size and granular, non-fibrillar presentation make it suitable for use as an injectable hemostat in patients with a hemorrhage or other emergency under antiplatelet therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04483245
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood sampling
Trials testing the same drug.
- NCT07372859 — Women's Heart: Impact of Ultra-endurance and Hormonal Profile on Cardiac and Systemic Inflammatory Parameters in Female · NA · not yet recruiting
- NCT07237984 — Colorectal Omics and ofCS Proteoglycans (COCO) in Screening and a Diagnostic Pathway · not yet recruiting
- NCT06544018 — Circadian Rhythm Deregulation in Patients With CAPS · NA · recruiting
- NCT07245550 — Thyroid and Adrenal Disorders in ICU · not yet recruiting
- NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting
Other Centre Hospitalier Universitaire Dijon trials
Trials by the same sponsor.
- NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
- NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
- NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
- NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
- NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04483245 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
- Last refreshed: 25 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04483245.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing